Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q3 EPS by 40c
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q3 EPS of ($1.26), $0.40 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $27.77 million versus the consensus estimate of $53.9 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Electra Therapeutics files for proposed IPO
- Jefferies Starts Schloss Bangalore Ltd (THELEELA:IN) at Buy
- Zentek shares to move from Nasdaq to OTC Markets on Sept. 2
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
